Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
espond to a collection of information unless it contains a yalid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/597,545-Conf. #2550
INFORMATION DISCLOSURE			CLOSURE	Filing Date	January 28, 2005
ST	STATEMENT BY APPLICANT (Use as many sheats as necessary)			First Nemed Inventor	Benny V. Jensen
				Ari Uniti	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	HOI-11502/16

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (#known)	MM-DD-YYYY			
	AA*	US-6,007,798	12-28-1999	Bohn et al.		
	AB*	US-20030083322-A1	05-01-2003	KRAEMER et al.		
	AC*	US-5,728,373	03-17-1998	Alert et al.		
	AD*	US-20010053347-A1	12-20-2001	VARANI et al.		
	AE*	US-20050142092-A1	06-30-2005	Lintner		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cita	Foreign Palent Document	Publication Date MM-OD-YYYY	Name of Patentee or Applicant of Cited Occument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Г
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				To
	ВА	FR-FR2805744	09-07-2001	Sederma Sa		_
	ВВ	DE-DE19900749	07-13-2000	Aventis Pharma Gmbh		
	BC	JP-JP2002284647	10-03-2002	Cosmo Products Kk		
	BD	DE-DE19604190	08-07-1997	Hoechst Ag		
	BE	WO-WO 96/26712	09-06-1996	Hendelman Joseph H et al.		-
	BF	WO-WO 02/064088	08-22-2002	Nlazi Sarfaraz K		
	BG	WO-WO 9404129	03-03-1994	Belersdorf Ag et al.		\vdash
	BH	WO-WO 03068141	08-21-2003	Sederma et al.		

"EXAMINER: initial if reference considered, whether or not cliation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered, include copy of this form with next communication is applicant. "CITE NO.: Those application(s) which are marked with an single esterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(s)[2](iii)) because that applicant was fider direr June 30, 2010 is available in the iFPV. "Applicant's unique citation designation number (epitional). "See Kinds Codes of USPTO Patent Occuments at https://www.nextendor.org/linear/septiment/sep

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), dale, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CA	KLIGMAN et al., Collagen Loss In Photoaged Human Skin Is Overestimated By Histochemistry; Photodermatol Photoimmunol & Photomed; 2000; Pages 224-228			
	СВ	BERNSTEIN et al., The Biology of Angiotensin II Receptors; American Journal of Kidney Diseases, Vol 22, No. 5; Pages 745-754; November 1993			
	CC	PIERRE-LOUIS THARAUX et al., Anglotensin II Activates Collagen I Gene Through A Mechanism Involving The MAP/ER Kinase Pathway; American Heart Association, Inc.; Pages 330-336; February 2000;			
	CD	PATTEN et al., Effects of Angiotensin II Receptor Blockade Versus Angiotensin-Converting- Enzyme Inhibition On Ventricular Remodelling Following Myocardiel Infarction In The Mouse; The Biochemical Society and the Medical Research Society; Pages 109-118; 2003			

^{*}EXAMINER: Initial If reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation # not in conformance end not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is ettached.

Examiner i	Date
Signature	Considered